A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function
Latest Information Update: 08 Jul 2020
At a glance
- Drugs Dabrafenib (Primary)
- Indications Brain metastases; Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 09 Jan 2020 Status changed from recruiting to completed.
- 02 Jul 2019 Planned End Date changed from 4 Feb 2020 to 2 Oct 2019.
- 02 Jul 2019 Planned primary completion date changed from 9 Aug 2019 to 2 Oct 2019.